Free shipping on all orders over $ 500

ReACp53

Cat. No. M21693
ReACp53 Structure
Synonym:

HRRRRRRRRRRPILTRITLE-OH

Size Price Availability
10mg USD 430  USD430 Custom Synthesis
25mg USD 760  USD760 Custom Synthesis
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ReACp53 is a cell-penetrating peptide inhibitor of p53 aggregation, inhibits p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC). ReACp53 penetrates into HGSOC primary cancer cells and converts mutant p53 from a punctate state into soluble WT-like p53. ReACp53 also induces cancer cell death, cell cycle arrest and results in p53 degradation.

Administration of ReACp53 results in a significant increase in p21 and MDM2 transcription in OVCAR3 but not MCF7 xenografts. A significantly increased population is also found in G0/G1 phase, supporting proliferative arrest upon ReACp53 administration in vivo.

Chemical Information
Molecular Weight 2617.13
Formula C108H206N52O24
Solubility (25°C) DMSO 90 mg/mL
Water 25 mg/mL
Storage -20°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Adam Neal, et al. Cancers (Basel). Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers

[2] Jiangtao Lei, et al. Phys Chem Chem Phys. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation

[3] Yaqun Zhang, et al. Prostate Cancer Prostatic Dis. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC

[4] Y Zhang, et al. Oncogene. Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp

[5] Alice Soragni, et al. Cancer Cell. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Related p53 Products
SCH529074

SCH529074 is an orally active, potent activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.

BAY 1892005

BAY 1892005, a p53 protein modulator, is active on p53 condensates and does not lead to mutant p53 reactivation.

FOXO4-DRI

FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53.

p53 (17-26)

p53 (17-26) is amino acids 17 to 26 fragment of p53.

Azurin p28 peptide

Azurin p28 peptide is a tumor-penetrated antitumor peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: ReACp53, HRRRRRRRRRRPILTRITLE-OH supplier, p53, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.